臨床腫瘍学次世代シーケンスの世界市場規模調査＆予測、技術別、ワークフロー別、用途別、最終用途別、地域別分析、2023～2030年

世界の臨床腫瘍学次世代シーケンス市場は、2022年に約3億7,000万米ドルと評価され、予測期間2023年から2030年にかけて15.70％以上の健全な成長率で成長すると予測されています。

臨床腫瘍学次世代シーケンシング（次世代シーケンス）とは、腫瘍学分野、特にがんの診断と管理のための高度なゲノムシーケンス技術の応用を指します。次世代シーケンスは、複数の遺伝子またはゲノム領域の同時解析を可能にするハイスループットシーケンス技術であり、腫瘍に関する包括的な遺伝子情報を提供します。臨床腫瘍学次世代シーケンス市場は、がん疾患の有病率の上昇、解決策を発明するための研究開発活動への投資の増加、がんの効果的なPM診断・治療法の開発を誘発する医療費の増加などの要因により拡大しています。

がんの有病率の増加は、世界中でがん研究イニシアチブの急速な拡大に拍車をかけています。次世代シーケンス技術はがんゲノム研究の礎石となり、様々ながん種の複雑な遺伝的状況を解明するための大規模なゲノム研究や共同研究を促進しています。国際がん研究機関（IARC）の推計によると、2021年には世界中で約190万人の新規がん患者が発生し、2040年には2,750万人に増加すると予測されています。さらに、市場の主要参入企業は、プレシジョン・オンコロジーにおける次世代シーケンスの臨床利用のための新しいプラットフォームを開発しており、市場の成長をもたらしています。例えば、この業界の大手企業であるサーモフィッシャーサイエンティフィック社は、2022年8月、精密腫瘍学バイオマーカー検査をより広く利用できるようにするため、次世代シーケンス分析・検査ソフトウェアCE-IVD（IVDD）を発売しました。このソフトウェアにより、医療専門家はゲノム検査の結果を迅速に評価することができます。このソフトウェアは、支持される推奨、治療、臨床研究、査読付き文献などの適切なデータに照らして変動データを評価します。このような次世代シーケンス臨床用途の発展は、消費者の需要を高める可能性があります。さらに、次世代シーケンシング（次世代シーケンス）の技術的進歩、コンパニオン診断と個別化医療の採用拡大が、市場に有利な機会を生み出しています。しかし、データ管理のための計算効率の不足が、2023～2030年の予測期間を通じて市場の成長を阻害しています。

世界の臨床腫瘍学次世代シーケンス市場調査において考慮した主な地域は、アジア太平洋、北米、欧州、ラテンアメリカ、中東＆アフリカです。北米は、主要市場参入企業の優位性、精密腫瘍学の研究開発の高まり、製品開発への投資の増加、医療産業への政府支援の高まりにより、2022年の市場を独占しました。アジア太平洋は、がん罹患率の上昇、医療費の増加、がん治療薬開発活動への政府投資の増加などの要因により、市場において著しい成長を遂げると予測されています。

本調査の目的は、近年のさまざまなセグメントと国の市場規模を明らかにし、今後数年間の市場規模を予測することです。本レポートは、調査対象国における業界の質的・量的側面を盛り込むよう設計されています。

また、市場の将来的な成長を規定する促進要因や課題などの重要な側面に関する詳細情報も提供しています。さらに、主要企業の競合情勢や技術提供の詳細な分析とともに、利害関係者が投資するためのミクロ市場における潜在的な機会も組み込んでいます。

目次

第1章 エグゼクティブサマリー

第2章 世界の臨床腫瘍学次世代シーケンス市場の定義と範囲

• 調査目的
• 市場の定義と範囲
  • 業界の進化
  • 調査範囲
• 調査対象年
• 通貨換算レート

第3章 臨床腫瘍学次世代シーケンスの世界市場力学

• 臨床腫瘍学次世代シーケンス市場の影響分析（2020年～2030年）
  • 市場促進要因
    • がんの罹患率の増加
    • 解決策を発明するための研究開発活動への投資の増加
    • 医療支出の増加により、がんの効果的なPM診断・治療法の開発が加速
  • 市場の課題
    • データ管理のための計算効率の欠如
  • 市場機会
    • 次世代シーケンス（次世代シーケンス）の技術的進歩
    • コンパニオン診断と個別化医療の採用拡大

第4章 世界の臨床腫瘍学次世代シーケンス市場産業分析

• ポーターの5フォースモデル
  • 供給企業の交渉力
  • 買い手の交渉力
  • 新規参入業者の脅威
  • 代替品の脅威
  • 競争企業間の敵対関係
• ポーターの5フォース影響分析
• PEST分析
  • 政治
  • 経済
  • 社会
  • 技術
  • 環境
  • 法律
• 主な投資機会
• 主要成功戦略
• COVID-19影響分析
• 破壊的動向
• 業界専門家の視点
• アナリストの結論・提言

第5章 臨床腫瘍学の次世代シーケンスの世界市場：技術別

• 市場スナップショット
• 臨床腫瘍学次世代シーケンスの世界市場：技術別、実績・ポテンシャル分析
• 臨床腫瘍学次世代シーケンスの世界市場：技術別、推定・予測、2020～2030年
• 臨床腫瘍学次世代シーケンス市場、サブセグメント分析
  • 全ゲノムシーケンス
  • 全エクソームシーケンス
  • 対象シーケンスとリシーケンス

第6章 臨床腫瘍学次世代シーケンスの世界市場：ワークフロー別

• 市場スナップショット
• 臨床腫瘍学次世代シーケンスの世界市場：ワークフロー別、実績・ポテンシャル分析
• 臨床腫瘍学次世代シーケンスの世界市場推計・予測：2020年～2030年
• 臨床腫瘍学次世代シーケンス市場、サブセグメント分析
  • 次世代シーケンスプレシーケンス
  • 次世代シーケンスシーケンス
  • 次世代シーケンスデータ解析

第7章 臨床腫瘍学次世代シーケンスの世界市場：用途別

• 市場スナップショット
• 臨床腫瘍学次世代シーケンスの世界市場：用途別、実績・ポテンシャル分析
• 臨床腫瘍学次世代シーケンスの世界市場：用途別、推定・予測、2020～2030年
• 臨床腫瘍学次世代シーケンス市場、サブセグメント分析
  • スクリーニング
  • コンパニオン診断
  • その他

第8章 臨床腫瘍学次世代シーケンスの世界市場：最終用途別

• 市場スナップショット
• 臨床腫瘍学次世代シーケンスの世界市場：最終用途別、実績・ポテンシャル分析
• 臨床腫瘍学次世代シーケンスの世界市場：最終用途別、推定・予測、2020～2030年
• 臨床腫瘍学次世代シーケンス市場、サブセグメント分析
  • 病院
  • クリニック
  • 研究所

第9章 臨床腫瘍学次世代シーケンスの世界市場：地域別分析

• 主要国
• 主な新興国
• 臨床腫瘍学次世代シーケンス市場、地域別市場スナップショット
• 北米
  • 米国
    • 技術別、推定・予測、2020～2030年
    • ワークフロー、推定・予測、2020～2030年
    • 用途別、推定・予測、2020～2030年
    • 最終用途、推定・予測、2020～2030年
  • カナダ
• 欧州の臨床腫瘍学次世代シーケンス市場スナップショット
  • 英国
  • ドイツ
  • フランス
  • スペイン
  • イタリア
  • その他の欧州
• アジア太平洋の臨床腫瘍学次世代シーケンス市場スナップショット
  • 中国
  • インド
  • 日本
  • オーストラリア
  • 韓国
  • その他のアジア太平洋
• ラテンアメリカの臨床腫瘍学次世代シーケンス市場スナップショット
  • ブラジル
  • メキシコ
• 中東・アフリカ
  • サウジアラビア
  • 南アフリカ
  • その他の中東およびアフリカ

第10章 競合情報

• 主要企業のSWOT分析
• 主要市場戦略
• 企業プロファイル
  • Illumina, Inc.
    • 主要情報
    • 概要
    • 財務（データの入手可能性によります）
    • 製品概要
  • Thermo Fisher Scientific Inc.
  • F. Hoffmann-La Roche Ltd
  • Agilent Technologies, Inc.
  • Myriad Genetics, Inc.
  • Beijing Genomics Institute（BGI）
  • Perkin Elmer, Inc.
  • Oxford Nanopore Technologies
  • Paradigm Diagnostics, Inc.
  • PerkinElmer, Inc.

第11章 調査プロセス

• 調査プロセス
  • データ鉱業
  • 分析
  • 市場推定
  • 検証
  • 出版
• 調査属性
• 調査前提条件

LIST OF TABLES

• TABLE 1. Global Clinical Oncology Next Generation Sequencing Market, report scope
• TABLE 2. Global Clinical Oncology Next Generation Sequencing Market estimates & forecasts by Region 2020-2030 (USD Million)
• TABLE 3. Global Clinical Oncology Next Generation Sequencing Market estimates & forecasts by Technology 2020-2030 (USD Million)
• TABLE 4. Global Clinical Oncology Next Generation Sequencing Market estimates & forecasts by Workflow 2020-2030 (USD Million)
• TABLE 5. Global Clinical Oncology Next Generation Sequencing Market estimates & forecasts by Application 2020-2030 (USD Million)
• TABLE 6. Global Clinical Oncology Next Generation Sequencing Market estimates & forecasts by End-use 2020-2030 (USD Million)
• TABLE 7. Global Clinical Oncology Next Generation Sequencing Market by segment, estimates & forecasts, 2020-2030 (USD Million)
• TABLE 8. Global Clinical Oncology Next Generation Sequencing Market by region, estimates & forecasts, 2020-2030 (USD Million)
• TABLE 9. Global Clinical Oncology Next Generation Sequencing Market by segment, estimates & forecasts, 2020-2030 (USD Million)
• TABLE 10. Global Clinical Oncology Next Generation Sequencing Market by region, estimates & forecasts, 2020-2030 (USD Million)
• TABLE 11. Global Clinical Oncology Next Generation Sequencing Market by segment, estimates & forecasts, 2020-2030 (USD Million)
• TABLE 12. Global Clinical Oncology Next Generation Sequencing Market by region, estimates & forecasts, 2020-2030 (USD Million)
• TABLE 13. Global Clinical Oncology Next Generation Sequencing Market by segment, estimates & forecasts, 2020-2030 (USD Million)
• TABLE 14. Global Clinical Oncology Next Generation Sequencing Market by region, estimates & forecasts, 2020-2030 (USD Million)
• TABLE 15. Global Clinical Oncology Next Generation Sequencing Market by segment, estimates & forecasts, 2020-2030 (USD Million)
• TABLE 16. Global Clinical Oncology Next Generation Sequencing Market by region, estimates & forecasts, 2020-2030 (USD Million)
• TABLE 17. U.S. Clinical Oncology Next Generation Sequencing Market estimates & forecasts, 2020-2030 (USD Million)
• TABLE 18. U.S. Clinical Oncology Next Generation Sequencing Market estimates & forecasts by segment 2020-2030 (USD Million)
• TABLE 19. U.S. Clinical Oncology Next Generation Sequencing Market estimates & forecasts by segment 2020-2030 (USD Million)
• TABLE 20. Canada Clinical Oncology Next Generation Sequencing Market estimates & forecasts, 2020-2030 (USD Million)
• TABLE 21. Canada Clinical Oncology Next Generation Sequencing Market estimates & forecasts by segment 2020-2030 (USD Million)
• TABLE 22. Canada Clinical Oncology Next Generation Sequencing Market estimates & forecasts by segment 2020-2030 (USD Million)
• TABLE 23. UK Clinical Oncology Next Generation Sequencing Market estimates & forecasts, 2020-2030 (USD Million)
• TABLE 24. UK Clinical Oncology Next Generation Sequencing Market estimates & forecasts by segment 2020-2030 (USD Million)
• TABLE 25. UK Clinical Oncology Next Generation Sequencing Market estimates & forecasts by segment 2020-2030 (USD Million)
• TABLE 26. Germany Clinical Oncology Next Generation Sequencing Market estimates & forecasts, 2020-2030 (USD Million)
• TABLE 27. Germany Clinical Oncology Next Generation Sequencing Market estimates & forecasts by segment 2020-2030 (USD Million)
• TABLE 28. Germany Clinical Oncology Next Generation Sequencing Market estimates & forecasts by segment 2020-2030 (USD Million)
• TABLE 29. France Clinical Oncology Next Generation Sequencing Market estimates & forecasts, 2020-2030 (USD Million)
• TABLE 30. France Clinical Oncology Next Generation Sequencing Market estimates & forecasts by segment 2020-2030 (USD Million)
• TABLE 31. France Clinical Oncology Next Generation Sequencing Market estimates & forecasts by segment 2020-2030 (USD Million)
• TABLE 32. Italy Clinical Oncology Next Generation Sequencing Market estimates & forecasts, 2020-2030 (USD Million)
• TABLE 33. Italy Clinical Oncology Next Generation Sequencing Market estimates & forecasts by segment 2020-2030 (USD Million)
• TABLE 34. Italy Clinical Oncology Next Generation Sequencing Market estimates & forecasts by segment 2020-2030 (USD Million)
• TABLE 35. Spain Clinical Oncology Next Generation Sequencing Market estimates & forecasts, 2020-2030 (USD Million)
• TABLE 36. Spain Clinical Oncology Next Generation Sequencing Market estimates & forecasts by segment 2020-2030 (USD Million)
• TABLE 37. Spain Clinical Oncology Next Generation Sequencing Market estimates & forecasts by segment 2020-2030 (USD Million)
• TABLE 38. RoE Clinical Oncology Next Generation Sequencing Market estimates & forecasts, 2020-2030 (USD Million)
• TABLE 39. RoE Clinical Oncology Next Generation Sequencing Market estimates & forecasts by segment 2020-2030 (USD Million)
• TABLE 40. RoE Clinical Oncology Next Generation Sequencing Market estimates & forecasts by segment 2020-2030 (USD Million)
• TABLE 41. China Clinical Oncology Next Generation Sequencing Market estimates & forecasts, 2020-2030 (USD Million)
• TABLE 42. China Clinical Oncology Next Generation Sequencing Market estimates & forecasts by segment 2020-2030 (USD Million)
• TABLE 43. China Clinical Oncology Next Generation Sequencing Market estimates & forecasts by segment 2020-2030 (USD Million)
• TABLE 44. India Clinical Oncology Next Generation Sequencing Market estimates & forecasts, 2020-2030 (USD Million)
• TABLE 45. India Clinical Oncology Next Generation Sequencing Market estimates & forecasts by segment 2020-2030 (USD Million)
• TABLE 46. India Clinical Oncology Next Generation Sequencing Market estimates & forecasts by segment 2020-2030 (USD Million)
• TABLE 47. Japan Clinical Oncology Next Generation Sequencing Market estimates & forecasts, 2020-2030 (USD Million)
• TABLE 48. Japan Clinical Oncology Next Generation Sequencing Market estimates & forecasts by segment 2020-2030 (USD Million)
• TABLE 49. Japan Clinical Oncology Next Generation Sequencing Market estimates & forecasts by segment 2020-2030 (USD Million)
• TABLE 50. South Korea Clinical Oncology Next Generation Sequencing Market estimates & forecasts, 2020-2030 (USD Million)
• TABLE 51. South Korea Clinical Oncology Next Generation Sequencing Market estimates & forecasts by segment 2020-2030 (USD Million)
• TABLE 52. South Korea Clinical Oncology Next Generation Sequencing Market estimates & forecasts by segment 2020-2030 (USD Million)
• TABLE 53. Australia Clinical Oncology Next Generation Sequencing Market estimates & forecasts, 2020-2030 (USD Million)
• TABLE 54. Australia Clinical Oncology Next Generation Sequencing Market estimates & forecasts by segment 2020-2030 (USD Million)
• TABLE 55. Australia Clinical Oncology Next Generation Sequencing Market estimates & forecasts by segment 2020-2030 (USD Million)
• TABLE 56. RoAPAC Clinical Oncology Next Generation Sequencing Market estimates & forecasts, 2020-2030 (USD Million)
• TABLE 57. RoAPAC Clinical Oncology Next Generation Sequencing Market estimates & forecasts by segment 2020-2030 (USD Million)
• TABLE 58. RoAPAC Clinical Oncology Next Generation Sequencing Market estimates & forecasts by segment 2020-2030 (USD Million)
• TABLE 59. Brazil Clinical Oncology Next Generation Sequencing Market estimates & forecasts, 2020-2030 (USD Million)
• TABLE 60. Brazil Clinical Oncology Next Generation Sequencing Market estimates & forecasts by segment 2020-2030 (USD Million)
• TABLE 61. Brazil Clinical Oncology Next Generation Sequencing Market estimates & forecasts by segment 2020-2030 (USD Million)
• TABLE 62. Mexico Clinical Oncology Next Generation Sequencing Market estimates & forecasts, 2020-2030 (USD Million)
• TABLE 63. Mexico Clinical Oncology Next Generation Sequencing Market estimates & forecasts by segment 2020-2030 (USD Million)
• TABLE 64. Mexico Clinical Oncology Next Generation Sequencing Market estimates & forecasts by segment 2020-2030 (USD Million)
• TABLE 65. RoLA Clinical Oncology Next Generation Sequencing Market estimates & forecasts, 2020-2030 (USD Million)
• TABLE 66. RoLA Clinical Oncology Next Generation Sequencing Market estimates & forecasts by segment 2020-2030 (USD Million)
• TABLE 67. RoLA Clinical Oncology Next Generation Sequencing Market estimates & forecasts by segment 2020-2030 (USD Million)
• TABLE 68. Saudi Arabia Clinical Oncology Next Generation Sequencing Market estimates & forecasts, 2020-2030 (USD Million)
• TABLE 69. South Africa Clinical Oncology Next Generation Sequencing Market estimates & forecasts by segment 2020-2030 (USD Million)
• TABLE 70. RoMEA Clinical Oncology Next Generation Sequencing Market estimates & forecasts by segment 2020-2030 (USD Million)
• TABLE 71. List of secondary sources, used in the study of global Clinical Oncology Next Generation Sequencing Market
• TABLE 72. List of primary sources, used in the study of global Clinical Oncology Next Generation Sequencing Market
• TABLE 73. Years considered for the study
• TABLE 74. Exchange rates considered

List of tables and figures and dummy in nature, final lists may vary in the final deliverable

LIST OF FIGURES

• FIG 1. Global Clinical Oncology Next Generation Sequencing Market, research methodology
• FIG 2. Global Clinical Oncology Next Generation Sequencing Market, Market estimation techniques
• FIG 3. Global Market size estimates & forecast methods
• FIG 4. Global Clinical Oncology Next Generation Sequencing Market, key trends 2022
• FIG 5. Global Clinical Oncology Next Generation Sequencing Market, growth prospects 2023-2030
• FIG 6. Global Clinical Oncology Next Generation Sequencing Market, porters 5 force model
• FIG 7. Global Clinical Oncology Next Generation Sequencing Market, pest analysis
• FIG 8. Global Clinical Oncology Next Generation Sequencing Market, value chain analysis
• FIG 9. Global Clinical Oncology Next Generation Sequencing Market by segment, 2020 & 2030 (USD Million)
• FIG 10. Global Clinical Oncology Next Generation Sequencing Market by segment, 2020 & 2030 (USD Million)
• FIG 11. Global Clinical Oncology Next Generation Sequencing Market by segment, 2020 & 2030 (USD Million)
• FIG 12. Global Clinical Oncology Next Generation Sequencing Market by segment, 2020 & 2030 (USD Million)
• FIG 13. Global Clinical Oncology Next Generation Sequencing Market by segment, 2020 & 2030 (USD Million)
• FIG 14. Global Clinical Oncology Next Generation Sequencing Market, regional snapshot 2020 & 2030
• FIG 15. North America Clinical Oncology Next Generation Sequencing Market 2020 & 2030 (USD Million)
• FIG 16. Europe Clinical Oncology Next Generation Sequencing Market 2020 & 2030 (USD Million)
• FIG 17. Asia pacific Clinical Oncology Next Generation Sequencing Market 2020 & 2030 (USD Million)
• FIG 18. Latin America Clinical Oncology Next Generation Sequencing Market 2020 & 2030 (USD Million)
• FIG 19. Middle East & Africa Clinical Oncology Next Generation Sequencing Market 2020 & 2030 (USD Million)

List of tables and figures and dummy in nature, final lists may vary in the final deliverable

Global Clinical Oncology Next Generation Sequencing Market is valued at approximately USD 370.0 million in 2022 and is anticipated to grow with a healthy growth rate of more than 15.70% over the forecast period 2023-2030. Clinical Oncology Next Generation Sequencing (NGS) refers to the application of advanced genomic sequencing technologies in the field of oncology, specifically for diagnosing and managing cancer. NGS is a high-throughput sequencing technique that enables the simultaneous analysis of multiple genes or genomic regions, providing comprehensive genetic information about a tumor. The Clinical Oncology Next Generation Sequencing market is expanding because of factors such as rising prevelance of cancer disorders, rising investment in research & development activities to invent solutions and growing healthcare expenditure triggering development of effective PM diagnostic & therapeutic procedure for cancer.

The increasing prevalence of cancer has spurred a rapid expansion of cancer research initiatives worldwide. NGS technology has become a cornerstone in cancer genomics research, facilitating large-scale genomic studies and collaborative efforts to unravel the complex genetic landscape of various cancer types. These research efforts contribute to the development of novel therapies, identification of new targets, and improved understanding of cancer biology. according to estimates from the International Agency for Research on Cancer (IARC), in year 2021 there were around 1.9 million new cancer cases across the world, and it is projected to increase at 27.5 million new cases by year 2040, worldwide. Moreover, key market players in the market are developing new platforms for the clinical uses of NGS in precision oncology resulting in market growth. For instance, a major company in the industry, In August 2022, Thermo Fisher Scientific launched NGS Analysis and Test Software CE-IVD (IVDD) in order to make precision oncology biomarker testing more widely available. Healthcare professionals can swiftly assess the outcomes of genomic tests thanks to this software. The software evaluates the variation data in light of pertinent data, such as supported recommendations, treatments, clinical studies, and peer-reviewed literature. Such developments in NGS clinical applications may increase consumer demand. In addition, technological advancements in next-generation sequencing (NGS) and growing adoption of companion diagnostics and personalized medicine is creating a lucrative opportunity in the market. However, the lack of computational efficiency for data management stifles market growth throughout the forecast period of 2023-2030.

The key regions considered for the Global Clinical Oncology Next Generation Sequencing Market study includes Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 owing to the dominance of key market players, rising research and development for precision oncology, rising investment in development of product, and rising government support to the healthcare industry. Asia Pacific is projected to have significant growth in the market space owing to factors such as rising prevelance of cancer, rising healthcare expenditure and rising government investment in oncology drug development activities.

Major market player included in this report are:

• Illumina, Inc.
• Thermo Fisher Scientific Inc.
• F. Hoffmann-La Roche Ltd
• Agilent Technologies, Inc.
• Myriad Genetics, Inc.
• Beijing Genomics Institute (BGI)
• Perkin Elmer, Inc.
• Oxford Nanopore Technologies
• Paradigm Diagnostics, Inc.
• PerkinElmer, Inc.

Recent Developments in the Market:

• In February 2023, F. Hoffmann-La Roche Ltd. and Janssen Biotech Inc. (Janssen) expanded their collaboration in order to create companion diagnostics for targeted treatments and to include a wide spectrum of companion diagnostics, including tissue- and blood-based biomarkers, digital pathology, and sequencing pathology.
• In June 2023, Illumina Inc., a producer of DNA sequencing and array-based technologies, developed the artificial intelligence system PrimateAI-3D, which had previously unheard-of accuracy in foretelling disease-causing genetic defects in individuals.

Global Clinical Oncology Next Generation Sequencing Market Report Scope:

• Historical Data: 2020 - 2021
• Base Year for Estimation: 2022
• Forecast period: 2023-2030
• Report Coverage: Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
• Segments Covered: Technology, Workflow, Type, End-use, Region
• Regional Scope: North America; Europe; Asia Pacific; Latin America; Middle East & Africa
• Customization Scope: Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and Technology offerings of key players. The detailed segments and sub-segment of the market are explained below.

By Technology:

• Whole Genome Sequencing
• Whole Exome Sequencing
• Targeted Sequencing & Resequencing

By Workflow:

• NGS Pre-Sequencing
• NGS Sequencing
• NGS Data Analysis

By Application:

• Screening
• Companion Diagnostics
• Others

By End-use:

• Hospitals
• Clinics
• Laboratories

By Region:

• North America
• U.S.
• Canada
• Europe
• UK
• Germany
• France
• Spain
• Italy
• ROE
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• RoAPAC
• Latin America
• Brazil
• Mexico
• Middle East & Africa
• Saudi Arabia
• South Africa
• Rest of Middle East & Africa

Table of Contents

Chapter 1. Executive Summary

• 1.1. Market Snapshot
• 1.2. Global & Segmental Market Estimates & Forecasts, 2020-2030 (USD Million)
  • 1.2.1. Clinical Oncology Next Generation Sequencing Market, by Region, 2020-2030 (USD Million)
  • 1.2.2. Clinical Oncology Next Generation Sequencing Market, by Technology, 2020-2030 (USD Million)
  • 1.2.3. Clinical Oncology Next Generation Sequencing Market, by Workflow, 2020-2030 (USD Million)
  • 1.2.4. Clinical Oncology Next Generation Sequencing Market, by Application, 2020-2030 (USD Million)
  • 1.2.5. Clinical Oncology Next Generation Sequencing Market, by End-use, 2020-2030 (USD Million)
• 1.3. Key Trends
• 1.4. Estimation Methodology
• 1.5. Research Assumption

Chapter 2. Global Clinical Oncology Next Generation Sequencing Market Definition and Scope

• 2.1. Objective of the Study
• 2.2. Market Definition & Scope
  • 2.2.1. Industry Evolution
  • 2.2.2. Scope of the Study
• 2.3. Years Considered for the Study
• 2.4. Currency Conversion Rates

Chapter 3. Global Clinical Oncology Next Generation Sequencing Market Dynamics

• 3.1. Clinical Oncology Next Generation Sequencing Market Impact Analysis (2020-2030)
  • 3.1.1. Market Drivers
    • 3.1.1.1. Increasing prevelance of cancer
    • 3.1.1.2. Rising investment in research & development activities to invent solutions.
    • 3.1.1.3. Growing healthcare expenditure triggering development of effective PM diagnostic & therapeutic procedure for cancer.
  • 3.1.2. Market Challenges
    • 3.1.2.1. Lack of computational efficiency for data management
  • 3.1.3. Market Opportunities
    • 3.1.3.1. Technological advancements in next-generation sequencing (NGS)
    • 3.1.3.2. Growing adoption of companion diagnostics and personalized medicine

Chapter 4. Global Clinical Oncology Next Generation Sequencing Market Industry Analysis

• 4.1. Porter's 5 Force Model
  • 4.1.1. Bargaining Power of Suppliers
  • 4.1.2. Bargaining Power of Buyers
  • 4.1.3. Threat of New Entrants
  • 4.1.4. Threat of Substitutes
  • 4.1.5. Competitive Rivalry
• 4.2. Porter's 5 Force Impact Analysis
• 4.3. PEST Analysis
  • 4.3.1. Political
  • 4.3.2. Economical
  • 4.3.3. Social
  • 4.3.4. Technological
  • 4.3.5. Environmental
  • 4.3.6. Legal
• 4.4. Top investment opportunity
• 4.5. Top winning strategies
• 4.6. COVID-19 Impact Analysis
• 4.7. Disruptive Trends
• 4.8. Industry Expert Perspective
• 4.9. Analyst Recommendation & Conclusion

Chapter 5. Global Clinical Oncology Next Generation Sequencing Market, by Technology

• 5.1. Market Snapshot
• 5.2. Global Clinical Oncology Next Generation Sequencing Market by Technology, Performance - Potential Analysis
• 5.3. Global Clinical Oncology Next Generation Sequencing Market Estimates & Forecasts by Technology 2020-2030 (USD Million)
• 5.4. Clinical Oncology Next Generation Sequencing Market, Sub Segment Analysis
  • 5.4.1. Whole Genome Sequencing
  • 5.4.2. Whole Exome Sequencing
  • 5.4.3. Targeted Sequencing & Resequencing

Chapter 6. Global Clinical Oncology Next Generation Sequencing Market, by Workflow

• 6.1. Market Snapshot
• 6.2. Global Clinical Oncology Next Generation Sequencing Market by Workflow, Performance - Potential Analysis
• 6.3. Global Clinical Oncology Next Generation Sequencing Market Estimates & Forecasts by Workflow 2020-2030 (USD Million)
• 6.4. Clinical Oncology Next Generation Sequencing Market, Sub Segment Analysis
  • 6.4.1. NGS Pre-Sequencing
  • 6.4.2. NGS Sequencing
  • 6.4.3. NGS Data Analysis

Chapter 7. Global Clinical Oncology Next Generation Sequencing Market, by Application

• 7.1. Market Snapshot
• 7.2. Global Clinical Oncology Next Generation Sequencing Market by Application, Performance - Potential Analysis
• 7.3. Global Clinical Oncology Next Generation Sequencing Market Estimates & Forecasts by Application 2020-2030 (USD Million)
• 7.4. Clinical Oncology Next Generation Sequencing Market, Sub Segment Analysis
  • 7.4.1. Screening
  • 7.4.2. Companion Diagnostics
  • 7.4.3. Others

Chapter 8. Global Clinical Oncology Next Generation Sequencing Market, by End-use

• 8.1. Market Snapshot
• 8.2. Global Clinical Oncology Next Generation Sequencing Market by End-use, Performance - Potential Analysis
• 8.3. Global Clinical Oncology Next Generation Sequencing Market Estimates & Forecasts by End-use 2020-2030 (USD Million)
• 8.4. Clinical Oncology Next Generation Sequencing Market, Sub Segment Analysis
  • 8.4.1. Hospitals
  • 8.4.2. Clinics
  • 8.4.3. Laboratories

Chapter 9. Global Clinical Oncology Next Generation Sequencing Market, Regional Analysis

• 9.1. Top Leading Countries
• 9.2. Top Emerging Countries
• 9.3. Clinical Oncology Next Generation Sequencing Market, Regional Market Snapshot
• 9.4. North America Clinical Oncology Next Generation Sequencing Market
  • 9.4.1. U.S. Clinical Oncology Next Generation Sequencing Market
    • 9.4.1.1. Technology breakdown estimates & forecasts, 2020-2030
    • 9.4.1.2. Workflow breakdown estimates & forecasts, 2020-2030
    • 9.4.1.3. Application breakdown estimates & forecasts, 2020-2030
    • 9.4.1.4. End-use breakdown estimates & forecasts, 2020-2030
  • 9.4.2. Canada Clinical Oncology Next Generation Sequencing Market
• 9.5. Europe Clinical Oncology Next Generation Sequencing Market Snapshot
  • 9.5.1. U.K. Clinical Oncology Next Generation Sequencing Market
  • 9.5.2. Germany Clinical Oncology Next Generation Sequencing Market
  • 9.5.3. France Clinical Oncology Next Generation Sequencing Market
  • 9.5.4. Spain Clinical Oncology Next Generation Sequencing Market
  • 9.5.5. Italy Clinical Oncology Next Generation Sequencing Market
  • 9.5.6. Rest of Europe Clinical Oncology Next Generation Sequencing Market
• 9.6. Asia-Pacific Clinical Oncology Next Generation Sequencing Market Snapshot
  • 9.6.1. China Clinical Oncology Next Generation Sequencing Market
  • 9.6.2. India Clinical Oncology Next Generation Sequencing Market
  • 9.6.3. Japan Clinical Oncology Next Generation Sequencing Market
  • 9.6.4. Australia Clinical Oncology Next Generation Sequencing Market
  • 9.6.5. South Korea Clinical Oncology Next Generation Sequencing Market
  • 9.6.6. Rest of Asia Pacific Clinical Oncology Next Generation Sequencing Market
• 9.7. Latin America Clinical Oncology Next Generation Sequencing Market Snapshot
  • 9.7.1. Brazil Clinical Oncology Next Generation Sequencing Market
  • 9.7.2. Mexico Clinical Oncology Next Generation Sequencing Market
• 9.8. Middle East & Africa Clinical Oncology Next Generation Sequencing Market
  • 9.8.1. Saudi Arabia Clinical Oncology Next Generation Sequencing Market
  • 9.8.2. South Africa Clinical Oncology Next Generation Sequencing Market
  • 9.8.3. Rest of Middle East & Africa Clinical Oncology Next Generation Sequencing Market

Chapter 10. Competitive Intelligence

• 10.1. Key Company SWOT Analysis
  • 10.1.1. Company 1
  • 10.1.2. Company 2
  • 10.1.3. Company 3
• 10.2. Top Market Strategies
• 10.3. Company Profiles
  • 10.3.1. Illumina, Inc.
    • 10.3.1.1. Key Information
    • 10.3.1.2. Overview
    • 10.3.1.3. Financial (Subject to Data Availability)
    • 10.3.1.4. Product Summary
    • 10.3.1.5. Recent Developments
  • 10.3.2. Thermo Fisher Scientific Inc.
  • 10.3.3. F. Hoffmann-La Roche Ltd
  • 10.3.4. Agilent Technologies, Inc.
  • 10.3.5. Myriad Genetics, Inc.
  • 10.3.6. Beijing Genomics Institute (BGI)
  • 10.3.7. Perkin Elmer, Inc.
  • 10.3.8. Oxford Nanopore Technologies
  • 10.3.9. Paradigm Diagnostics, Inc.
  • 10.3.10. PerkinElmer, Inc.

Chapter 11. Research Process

• 11.1. Research Process
  • 11.1.1. Data Mining
  • 11.1.2. Analysis
  • 11.1.3. Market Estimation
  • 11.1.4. Validation
  • 11.1.5. Publishing
• 11.2. Research Attributes
• 11.3. Research Assumption